4 transcripts
FGEN
Earnings call transcript
NASDAQ
2024 Q2
6 Aug 24
to pursue our strategic direction. Finally, and as we have continually communicated, we expect our cash, cash equivalents, and accounts receivable to fund our
FGEN
Earnings call transcript
NASDAQ
2024 Q1
6 May 24
. With the reduction in operating expenses and maintaining a disciplined capital allocation approach, as previously communicated, we expect our cash, cash equivalents
FGEN
Earnings call transcript
NASDAQ
2023 Q4
26 Feb 24
of $19.2 million year-over-year, reflecting our reduction in expenses as previously communicated through clinical trial shutdowns, SG&A efficiencies and U.S
FGEN
Earnings call transcript
NASDAQ
2023 Q2
7 Aug 23
communicated in the past, the deferred revenue balance in FibroGen China fluctuates based on management estimates of future revenue. As a result, FibroGen
- Prev
- 1
- Next